SecBot SecBot

EBS drug pipeline

$5.81
+0.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.6%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
9
1 bearish · 8 neutral
Phase 3 trials
1
1 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2007 (smallpox) and 2024 (mpox).

ACAM2000 smallpox and mpox (vaccinia) vaccine, live Updated Nov 2

What to watch

ACAM2000 is an approved, revenue-generating product with no pending FDA binary catalyst. Watch for U.S. government contract option exercises (the 10-year ASPR deal has annual renewals) and further international approvals, which drive lumpy quarterly revenue. The Q3 2026 revenue miss and lowered guidance are the near-term headwind to watch.

Bull case
  • ACAM2000 is one of only two FDA-approved vaccines for both smallpox and mpox, with a long track record since 2007 and a place in the U.S. Strategic National Stockpile.
  • The U.S. government has a 10-year contract with annual option renewals: a $56M modification in September 2025 and a $52.7M modification in June 2026, with total projected 2025 ACAM2000 sales exceeding $120 million.
  • International expansion is underway: Saudi Arabia approved ACAM2000 in May 2026 and Singapore approved an expanded mpox indication, opening new non-U.S. revenue streams.
Bear case
  • ACAM2000 faces competition from JYNNEOS (Bavarian Nordic), a safer non-replicating vaccine that the CDC prefers for mpox outbreaks and that has largely replaced ACAM2000 in clinical use.
  • ACAM2000 is a live replicating vaccinia virus vaccine with a known safety risk of myocarditis and other serious adverse reactions, limiting its addressable population.
  • Revenue is highly dependent on lumpy U.S. government contract timing: Q3 2026 Smallpox MCM product revenues (which include ACAM2000) fell 68% year-over-year due to delivery timing, contributing to a 52% total revenue decline and a net loss.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since March 2015.

ANTHRASIL anthrax immune globulin intravenous (human) Updated Nov 2

What to watch

ANTHRASIL has no upcoming FDA catalyst. Watch Emergent's broader financial performance, government contract awards (particularly BARDA contracts for its anthrax vaccine CYFENDUS and smallpox products), and the company's restructuring progress. The stock's sharp post-earnings decline reflects company-wide revenue pressure, not ANTHRASIL-specific news.

Bull case
  • ANTHRASIL is the only FDA-licensed polyclonal antibody therapeutic for inhalational anthrax, giving it a unique position in the biodefense market.
  • The drug is part of the U.S. Strategic National Stockpile, providing recurring government procurement revenue.
  • Ongoing biodefense funding and geopolitical tensions support sustained government demand for anthrax medical countermeasures.
Bear case
  • ANTHRASIL sales have been declining, with the company citing lower international sales (particularly to Canada) and the absence of international orders in recent quarters.
  • The drug's effectiveness is based solely on animal model studies, which limits its clinical evidence base and potential label expansion.
  • Emergent's overall financial performance is under severe pressure: Q3 2026 revenue fell 52% YoY to $110M, GAAP gross margin dropped to 14%, and the company reduced full-year 2026 guidance.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2013.

BAT botulism antitoxin heptavalent Updated Nov 2

What to watch

BAT is an already-approved, marketed product with no pending FDA decision. The next catalyst for Emergent is not BAT-specific but rather the pace of U.S. government contract awards and international orders, which drive lumpy quarterly revenue. Watch for further ASPR contract modifications or international BAT orders, as well as the company's Q4 2026 earnings for updates on the full-year guidance trajectory.

Bull case
  • BAT is the only FDA-approved product for treating symptomatic botulism across all seven botulinum neurotoxin serotypes (A through G) in adults and pediatric patients, giving it a unique, non-substitutable position in U.S. biodefense stockpiles.
  • Emergent received a $64.5 million contract modification from ASPR in May 2026 for BAT supply, demonstrating continued U.S. government commitment to stockpiling the product.
  • BAT is also approved by Health Canada, and the company reported an increase in international BAT sales in Q3 2026, partially offsetting lower U.S. government orders.
Bear case
  • BAT revenue is inherently lumpy and unpredictable, driven entirely by U.S. government and international procurement timing, not recurring commercial demand. Q3 2026 Other Product sales (including BAT) fell 87% YoY to $7.6M due to timing of USG BAT deliveries.
  • Emergent's overall financials are deteriorating: Q3 2026 total revenue fell 52% YoY, the company cut full-year 2026 guidance for the second time, and GAAP net loss was $32.7M versus net income of $51.2M a year earlier.
  • BAT faces no direct FDA-approved competitor for adult botulism, but the addressable market is tiny (botulism is rare) and entirely government-procurement driven, limiting revenue growth potential.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1970.

BioThrax anthrax vaccine adsorbed Updated Nov 2

What to watch

BioThrax is a mature, approved product with no pending FDA catalyst. The stock's next binary event is the Q4 2026 earnings report (likely Feb 2027), where the key question is whether Anthrax MCM revenue stabilizes after the Q3 miss and whether the CYFENDUS transition cannibalizes BioThrax further. Watch for DoD contract renewals on the $21.5M BioThrax delivery order (option periods for 2027-2028).

Bull case
  • BioThrax is a long-approved, sole-source biodefense vaccine for anthrax with a guaranteed government customer base (DoD, BARDA, foreign governments), providing recurring, non-discretionary revenue.
  • In January 2026, Emergent received a $21.5M delivery order from the U.S. Department of War for BioThrax, with option periods extending through 2028.
  • Anthrax MCM revenue (BioThrax + CYFENDUS + other anthrax products) increased $23.7M YoY in Q3 2026, driven by U.S. government procurement timing.
Bear case
  • BioThrax is being internally cannibalized by Emergent's own next-gen product CYFENDUS (approved July 2023), which uses the same active ingredient with an adjuvant for a shorter dosing schedule.
  • The company's Q3 2026 revenue fell 52% YoY to $110M, missing consensus of $123.2M, and full-year guidance was cut for the second time in 2026.
  • Emergent faces a securities fraud investigation (announced Aug 2026) and a CFO transition, adding governance risk.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market. CNJ-016 received initial FDA approval in 2005 and has been commercially available for nearly two decades.

CNJ-016 vaccinia immune globulin intravenous (human) Updated Nov 2

What to watch

CNJ-016 is already approved and generating revenue through government stockpile contracts. Watch for future ASPR contract option exercises under the existing 10-year agreement and any changes in U.S. biodefense spending priorities, which directly drive the drug's revenue stream. The next catalyst is not a binary regulatory event but continued contract awards, making this a slow-burn commercial story rather than a binary biotech bet.

Bull case
  • CNJ-016 is the only FDA-licensed polyclonal antibody therapeutic for complications from smallpox vaccination, giving it a unique, competition-free position in the U.S. Strategic National Stockpile.
  • A 10-year contract (2019) valued at ~$535M provides a long-term revenue backbone. In 2026 alone, ASPR exercised a $54M option (March) and a $51.9M contract modification (July 2025) was awarded, demonstrating sustained government demand.
  • Analyst consensus is bullish: 5 Buy/Strong Buy ratings vs 1 Hold and 1 Sell, with a mean price target of $11 (implied ~61.5% upside from the $6.81 close on Nov 2, 2026).
Bear case
  • Revenue concentration risk: The U.S. Government (HHS/ASPR) is the principal customer for CNJ-016, making the drug dependent on government biodefense budgets and political priorities.
  • Q3 2026 saw smallpox MCM revenues (including CNJ-016) drop 68% year-over-year, with lower USG and international sales of CNJ-016 cited as a factor. The company's total Q3 revenue fell 52% to $110M, and adjusted EBITDA swung to a $4.6M loss.
  • The stock fell ~18.6% in post-market trading on November 2, 2026, after Q3 earnings missed revenue estimates ($110M vs $123.22M consensus) and the company cut its 2026 outlook.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval July 20, 2023).

CYFENDUS anthrax vaccine adsorbed, adjuvanted Updated Nov 2

What to watch

CYFENDUS is already approved and generating government contract revenue; watch for future BARDA contract modifications and any label expansion (e.g., pediatric or older adult populations) that could open new procurement. The Phase 2 booster study (NCT05997264) is ongoing but not a near-term binary. The stock's next major catalyst is company-wide, not drug-specific: the Q3 2026 earnings just reported today (Nov 2) showed anthrax MCM revenue up $23.7M year-over-year on CYFENDUS timing, but overall revenue fell 52% and guidance was lowered.

Bull case
  • CYFENDUS offers a key advantage over the older BioThrax: it is a two-dose regimen versus three-dose, providing faster protection. This makes it more attractive for strategic national stockpiling.
  • The U.S. government continues to invest: a $24M BARDA contract modification was awarded in September 2026 for additional CYFENDUS doses, and a broader $250M multi-product contract package included $30M for CYFENDUS.
  • Q3 2026 anthrax MCM product revenues increased $23.7M year-over-year, primarily attributable to higher U.S. government sales of CYFENDUS due to timing.
Bear case
  • CYFENDUS competes with Emergent's own older product BioThrax, which may cannibalize sales. In Q4 2025, CYFENDUS product sales actually decreased, partially offsetting growth in BioThrax and ANTHRASIL sales.
  • The entire anthrax vaccine market is driven almost entirely by U.S. government biodefense procurement, not patient demand, making revenue lumpy and dependent on annual contract exercises and political priorities.
  • Emergent BioSolutions faces broader financial challenges: Q3 2026 total revenue fell 52% to $110M, GAAP gross margin collapsed to 14%, and the company lowered full-year 2026 guidance. The stock trades near multi-year lows around $5-6.
▼ bearish
Impact
PhaseApproved
Time to marketAlready approved and marketed (OTC since March 2023).

NARCAN naloxone hydrochloride Updated Nov 2

What to watch

Watch for continued erosion of NARCAN market share as three OTC competitors (RiVive, Rextovy, and Amneal's generic) intensify pricing pressure. Emergent's Q3 2026 earnings (Nov 2) showed naloxone revenue down 42% YoY, and the company cut full-year guidance. The next major catalyst is the Q4 2026 earnings report in early 2027, which will show whether the multipack strategy and Canadian expansion can offset U.S. market share losses.

Bull case
  • NARCAN was the first FDA-approved OTC naloxone product (March 2023) and remains the most recognized brand in the opioid overdose reversal market.
  • FDA approved new multipack configurations (6-count and 24-count) in February 2026, potentially improving cost-effectiveness and distribution efficiency.
  • Canadian sales of branded NARCAN partially offset U.S. declines in Q3 2026, and Emergent won a Canadian standing offer running through September 2029.
Bear case
  • NARCAN faces at least three OTC competitors: RiVive (Harm Reduction Therapeutics), Rextovy (Amphastar, approved June 2026), and Amneal's generic OTC naloxone, all driving aggressive pricing pressure.
  • Naloxone product revenue fell 42% YoY in Q3 2026 ($31.4M decline), driven by unfavorable price-volume mix in U.S. public interest channels.
  • Emergent recorded a $191.3M non-cash impairment on the NARCAN asset group in Q2 2026, reflecting management's reduced cash flow expectations.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approved June 2021).

TEMBEXA brincidofovir Updated Nov 2

What to watch

Watch for additional U.S. government (BARDA/ASPR) contract modifications for TEMBEXA stockpiling, which drive the drug's revenue. The mpox clinical trial in Africa (PANTHER study) could open a larger addressable market if results are positive, but that readout has no firm date yet. EBS reports full-year 2026 results in early 2027, which will show whether TEMBEXA deliveries continue to offset declines in other smallpox MCM products.

Bull case
  • TEMBEXA is the first and only FDA-approved oral smallpox antiviral for all age groups, including neonates, giving it a unique label advantage over TPOXX.
  • Emergent has secured multiple government contracts for TEMBEXA: $67.4 million in options (Sept 2024), a $17 million BARDA modification for oral suspension, and ongoing deliveries under a 10-year contract with the U.S. government.
  • The drug is being evaluated in a clinical trial for mpox (monkeypox) in Africa (PANTHER study), which could expand its addressable market beyond smallpox biodefense.
Bear case
  • TEMBEXA's smallpox market is almost entirely government stockpiling contracts, which are lumpy and subject to budget timing. Q3 2026 smallpox MCM revenue fell 68% YoY, though TEMBEXA USG sales were higher due to timing.
  • The drug carries an FDA boxed warning for increased mortality risk when used for longer than the recommended duration, which limits its appeal beyond acute smallpox treatment.
  • SIGA Technologies' TPOXX (tecovirimat) is the dominant smallpox antiviral with broader government stockpiling contracts globally and a head start (approved 2018 vs TEMBEXA's 2021).
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval December 21, 2020).

Ebanga ansuvimab-zykl Updated Nov 2

What to watch

Ebanga is already approved and commercialized with no pending regulatory binary. The next material event would be any new BARDA procurement option exercise or a new outbreak-driven order, neither of which is predictable or scheduled. Watch Emergent's quarterly contracts-and-grants revenue line for Ebanga-related development work, which has been declining (down 60% year-over-year in Q3 2026).

Bull case
  • Ebanga is one of only two FDA-approved treatments for Ebola virus disease, giving it a unique position in biodefense and pandemic preparedness.
  • Emergent holds a 10-year BARDA contract worth up to $704 million for advanced development and procurement of Ebanga, providing a long-term government revenue stream (BARDA contract).
  • The WHO officially recommends Ebanga (alongside Inmazeb) for Ebola treatment, supporting global adoption and potential stockpiling by governments.
Bear case
  • Ebanga is a small and declining contributor to Emergent's revenue: Q3 2026 contracts and grants revenue fell 60% year-over-year, primarily due to lower Ebanga development work (Emergent Q3 2026 earnings).
  • The Ebola treatment market is tiny and outbreak-dependent; the drug's commercial opportunity is limited to government stockpiling and sporadic outbreaks.
  • Emergent faces competition from Regeneron's Inmazeb (REGN-EB3), the other FDA-approved Ebola monoclonal antibody, which was also tested in the same PALM trial.

Other drugs in filings and trials

no drug report yet
  • raxibacumab Last: Approval · Dec 12, 2025

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Apr 30, 2026NARCANApproval+6.0%+14.3%
Dec 12, 2025raxibacumabApproval+5.2%+6.0%

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
CYFENDUSVELOCITY: An Anthrax Vaccine Clinical StudyPhase 3Completed · results3,689Aug 6, 2020
CHOP + CD4CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaPhase 2Terminated · results5Oct 2008